Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody

Margetuximab in HER2-positive metastatic breast cancer

(2023) William J Gradishar et al.   Future Oncology

Metastatic HER2-Positive Breast Cancer: Is There an Optimal Sequence of Therapy?

(2023) Naomi Dempsey et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Pathological response and predictive role of tumour-infiltrating lymphocytes in HER2-positive early breast cancer treated with neoadjuvant pyrotinib plus trastuzumab and chemotherapy (Panphila): a multicentre phase 2 trial

(2022) Zhenzhen Liu et al.   EUROPEAN JOURNAL OF CANCER

LBA19 Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer (PHILA): A randomized phase III trial

(2022) B. Xu et al.   ANNALS OF ONCOLOGY

Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

(2022) Hope S. Rugo et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer

(2021) Hope S. Rugo et al.   JAMA Oncology

Current and Future Management of HER2-Positive Metastatic Breast Cancer

(2021) Olga Martínez-Sáez et al.   JCO Oncology Practice

A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action

(2020) Xuesai Zhang et al.   MOLECULAR IMMUNOLOGY

Maternal Embryonic Leucine Zipper Kinase Promotes Tumor Growth and Metastasis via Stimulating FOXM1 Signaling in Esophageal Squamous Cell Carcinoma

(2020) Liang Chen et al.   Frontiers in Oncology

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

(2020) Sandra M Swain et al.   LANCET ONCOLOGY

Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study

(2020) Binghe Xu et al.   BREAST CANCER RESEARCH AND TREATMENT

Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I– III HER2‐Positive Breast Cancer: A Phase II Clinical Trial

(2020) Juncheng Xuhong et al.   ONCOLOGIST

The US Food and Drug Administration's Real‐World Evidence Framework: A Commitment for Engagement and Transparency on Real‐World Evidence

(2019) M. Khair ElZarrad et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience

(2019) Nicolò Matteo Luca Battisti et al.   BREAST CANCER RESEARCH AND TREATMENT

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer

(2019) Rashmi K. Murthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial

(2018) Sara A Hurvitz et al.   LANCET ONCOLOGY

Disparities of Trastuzumab Use in Resource‐Limited or Resource‐Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real‐World Study from China

(2017) Jianbin Li et al.   ONCOLOGIST

A phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients

(2015) Xinna Zhou et al.   SpringerPlus

Human Epidermal Growth Factor Receptor Family-Targeted Therapies in the Treatment of HER2-Overexpressing Breast Cancer

(2014) Z. Eroglu et al.   ONCOLOGIST

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

(2012) José Baselga et al.   LANCET

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER